Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 901–1,000 of 1,000
MASLD: Spatial Mechanisms and New Therapeutics
Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026) · Biomolecules · doi:10.3390/biom16081129
“…functions as a systemic metabolic back-bone therapy, particularly in patients with obesity, insulin resistance, or substantial cardiometabolic risk [8,111,113] Development beyond GLP-1 receptor mono-agonism largely reflects intensification of metabolic control rather than a fundamentally distinct…”
InfluentialRocca, F. L., Privitera, G., Geraci, C., Morello, V., Geraci, G., Paternò, V., Santoro, C., & Esposito, R. (2026) · Nutrients · doi:10.3390/nu18152527
“The phase 3 ESSENCE trial subsequently demonstrated that once-weekly semaglutide 2.4 mg significantly increased steatohepatitis resolution at interim analysis [244].”
InfluentialUnpacking adiposity: a narrative critical appraisal of diverse obesity definitions
Mancini, M. C., Halpern, B., de Melo, M. E., & Kramer, C. K. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02261-6
Combination therapy in metabolic dysfunction-associated steatohepatitis
Shibolet, O., & Katchman, H. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00151-2
A decade of transformation in MASLD: from nomenclature to novel therapies
Schattenberg, J. M., & Noureddin, M. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00087-7
Lee, Y. H., Nam, Y., Park, K., Ji, H., Kim, J. W., Cho, S., Kim, N. G., Kim, K., Yoo, J., Lee, J. Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1880176
“Likewise, incretin-based therapies, including GLP-1-directed approaches, provide meaningful metabolic benefits and signals of steatohepatitis improvement, yet anti-fibrotic responses remain variable across studies and patient populations (Sanyal et al., 2025).”
Shivega, W. G., Montgomery, J. R., Hack, M. A., Bolognese, A. C., Enestvedt, C. K., Maynard, E. C., Shaked, O., & Connelly, C. R. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.3205
Jin, J., Li, Y., Qiu, F., & Yan, D. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100857
Wohlfeld, C., Blas, A., Woodruff, J., Frick, M., Maciejewska, N., Patel, A., Grillo, C. A., Reagan, L. P., & Fadel, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742612
Rey, S. B., González, G. A., de la Plaza, I. R., Prieto, A. S., Lamelas, A. F., & Valenzuela, E. F. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2026.502837
Mazzola, A., Sultanik, P., Rebiha, A., Pais, R., Thabut, D., Scatton, O., Bourron, O., & Conti, F. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102899
Tsai, S. Y., Uwera, G. B., Roehm, B. A., Pandey, A., & VanWagner, L. B. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001209
Zhou, S., & Dong, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108369
First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management?
Ezhilarasan, D., & Sharmila, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104762
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?
Weiskirchen, R., & Lonardo, A. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.62
Diabetes Update 2026 – Neue Studienergebnisse und Erkenntnisse
Scherbaum, W. A. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01486-3
Li, J., Wu, H., Glaser, K. J., Ou, F., Manduca, A., Venkatesh, S. K., Sirlin, C. B., Loomba, R. S., Shah, V. H., Ehman, R. L., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001024
“…risk of advancing to cirrhosis and eventually HCC. [5,6] With the Food and Drug Administration approval of resmetirom and sem-aglutide for treating MASH patients with fibrosis stage 2–3, [7,8] accurate risk stratification to identify potentially eligible patients has become clinically critical.”
Bile acids as mediators of microbiota signaling in entero-hepatic disorders
Fiorucci, S., Marchianò, S., Giorgio, C. D., Urbani, G., Monti, M. C., Zampella, A., Distrutti, E., & Biagioli, M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118341 · Cited by 1
Akat, F., Bik, M. A., Habaci, A., Vatansev, H., Güngör, G., & Almaghrebi, E. (2026) · Clinical & Translational Metabolism · doi:10.1007/s12018-026-09335-z
Ramadan, A. M., Wakeel, L. M. E., Adel, A., Abdel‐Wahab, M., & Fahmy, S. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05157-x · Cited by 1
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
“In the phase 3 ESSENCE interim analysis, semaglutide 2.4 mg increased MASH resolution and fi brosis improvement at 72 weeks (106).”
InfluentialMantovani, A., & Lombardi, R. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104958
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
Cree, M. G., Dunsmoor-Su, R. F., Khoudary, S. R. E., Hurtado, M. D., Kapoor, E., Neal-Perry, G. S., & Santoro, N. F. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100321
“GLP-1 RAs induce long-term protective effects on cardiovascular health, renal outcomes, and adverse events in individuals with obesity and without T2D [42,43].”
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
“Semaglutide has shown powerful effects: a phase two trial (NEJM 2021) demonstrated NASH resolution without worsening fibrosis, and the ESSENCE phase three (NEJM 2025) confirmed significant improvements in both steatohepatitis and fibrosis (Sanyal et al., 2025).”
Miyake, T., Yoshida, O., Furukawa, S., Hirooka, M., Abe, M., Tokumoto, Y., Kanamoto, A., Watanabe, T., Yano, R., Okazaki, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71233
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Du, Y., Qi, L., Shi, Y., Huang, X., Shi, X., Liu, M., Fang, Y., & Hu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912000
“With resmetirom and semaglutide entering clinical practice, the therapeutic landscape of MASH is moving from single-mechanism targeting toward integrated metabolic management and pathology-based stratified intervention (75, 76).”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Banerjee, M., Roy, A., Sharma, V. M., & Das, A. (2026) · Obesity · doi:10.1002/oby.70277
Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver
Lewis, G. F., Feng, J. N., & Jin, T. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100023
Karlas, T., Messer, E. K., & Wiegand, J. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2906-2253
“For treatment monitoring and tailoring, future prospective data on laboratory and ultrasound-based NITs are of the utmost importance to adequately handle MASLD-specific therapeutic approaches.”
Keyserling, T. C., Wu, Q., Ammerman, A. S., Berkowitz, S. A., Buse, J. B., Couper, D. J., Evenson, K. R., Hursting, S., Sotres‐Alvarez, D., Lyons, K. M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29006 · Cited by 1
Niriella, M. A., Karunanayake, R. C., Wickramasuriya, H. P., & Silva, A. P. D. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100718
From prevalence to programme: Liver fibrosis screening after LiverScreen
Artru, F. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.017
Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications
Mohan, V., Kalra, S., Ahluwalia, A. I., Gangopadhyay, K. K., Bhattacharyya, A., Saboo, B., Kesavadev, J., Ramakrishnan, S., Lakhani, O., Nagendra, L., et al. (2026) · Cureus · doi:10.7759/cureus.114959
“…trials: Further broadened the evidence base into metabolic dysfunction-associated steatohepatitis and renal mechanistic pathways, respectively [35-37] Together, these programs show that confidence in reference semaglutide is grounded in a large, continuous, and product-specific body of…”
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Preoperative Medication Management in Ambulatory Surgery: Best Practices and Challenges
Villa, J. F., Dangler, L. A., Popovich, S., & Cata, J. P. (2026) · Current anesthesiology reports · doi:10.1007/s40140-026-00724-0
“GLP-1RAs are currently indicated for the treat-ment of type 2 diabetes mellitus and obesity [17– 19 ].”
Marshall, W. R., Sinha, S., Green, D., & Kalra, P. A. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001225
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“…of GLP-1 receptor agonists, GIP/GLP-1 dual receptor agonists, and GLP-1/GCGR dual receptor agonists are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and decreased appetite; some of these are related to dose escalation and the early phase of treatment [13,61,70].”
InfluentialMetabolic Syndrome: From Mechanisms to Therapeutic Interventions
Yan, M., & Xiang, Q. (2026) · MedComm · doi:10.1002/mco2.70934
“However, it does not improve the fibrosis stage [ 283, 366, 367 ].”
The instructive scar – the dynamic role of extracellular matrix in biliary pathophysiology
Waddell, S. H., Brennan, E., & Boulter, L. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052835
“Indeed, NOTCH has previously been described to promote fibrosis in non-cholestatic liver disease, particularly in individuals diagnosed with metabolic dysfunction-associated steatohepatitis (MASH) (Kang et al., 2023; Ramachandran et al., 2019).”
InfluentialPrieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
Hao, L., Khan, M. S. H., Zu, Y., & Wang, S. F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177621
“…in 62.9% of patients compared with 34.3% in the placebo group and fibrosis improvement without worsening of steatohepatitis observed in 36.8% versus 22.4%, respectively [17], highlighting heterogeneity in treatment response and the ongoing need for novel preventive and therapeutic strategies.”
InfluentialZhang, L., Liu, S., Zhao, Q., Liu, X., Sun, X., Li, F., Ye, M., Liu, M., Gao, L., & Zhao, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1899068
“Resmetirom and semaglutide have successively received approval from the U.S. Food and Drug Administration for the treatment of patients with NASH accompanied by stage 2 or 3 liver fibrosis or histologically confirmed NASH (Keam, 2024; Sanyal et al., 2025).”
Yamamoto, K., Baba, M., Kubo, A., Yamada, R., Nakamura, A., Morikawa, K., Ohara, M., Nakai, M., Sho, T., Suda, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177611
Coelho, V. S., & Coelho, L. R. P. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i3.615
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Semaglutide has also been shown to exert potent renoprotective effects in the FLOW study [15] and beneficial effects on metabolic dysfunction-associated steatotic liver disease and steato-hepatitis [16] (Fig.”
From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Chen, H., Li, L., Zhang, J., Zhu, S., Cornier, M., & Purnell, J. Q. (2026) · Obesity · doi:10.1002/oby.70263
Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which
Weglage, J., & Tacke, F. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.60
Qureshi, S. U., Khan, K. A., Wisal, A., Khan, R., & Ahmad, H. (2026) · Pakistan journal of Gastroenterology · doi:10.63521/641kea29
Li, Y., & Papadopoulos, V. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005135
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
Lünswilken, P., Worobiec, K., Braun, L. S., Altrogge, J., Schenk, A., Jegodzinski, L., Wilms, B., Marquardt, J. U., & Meyhöfer, S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag350
Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Flagiello, V., Barreby, E., Gentilucci, U. V., & Romeo, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70142
New therapeutic options for metabolic‐associated steatotic liver disease
Straatmijer, T., & Mulder, M. B. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70795
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Qin, Z., Guo, Q., Zhang, K., Lu, J., Wang, J., Li, Z., Zhong, L., Huang, Y., Li, Q., Zheng, X., et al. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109870
Meroueh, C., Ibrahim, S. H., Tizhoosh, H., Noh, Y., Kim, I. Y., Lucas, P., & Shah, V. H. (2026) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2026.100712
“13,14 In general, steatohepatitis is a pattern diagnosis, not an etiological verdict, with histopathological elements such as macrovesicular steatosis, hepatocellular ballooning, lobular in fl ammation, present in all SLDs. 15 Histopathologically, ASH is more often characterized by a neutrophil-rich…”
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Li, Z., Song, J., Ma, K., Tang, S., Wang, S., Ji, W., Lu, C., Zhang, T., Zheng, H., Zheng, X., et al. (2026) · Advanced Science · doi:10.1002/advs.77451
“Furthermore, gastrointestinal adverse events may compromise treatment adherence and patient tolerability [ 5, 6, 9, 10 ].”
InfluentialVolety, S., Rice, J., Lee, W., Doctor, C., Gwertzman, J., Boehm, G., Eriten, M., Pirasteh, A., Roldán‐Alzate, A., & Hernando, D. (2026) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2026.110782
Mahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Incretin-based therapies in hepatology practice
Durmuş, M. E., Köker, G., & Öcal, S. (2026) · World Journal of Hepatology · doi:10.4254/wjh.125275
Gkantsinikoudi, C., Dignam, J. P., Kumar, R., Jokl, E. J., Rana, M., Li, W., Samus, M., Landi, S., Athwal, V. S., Kendall, T. J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.207327 · Cited by 1
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177805
Lonardo, A., & Weiskirchen, R. (2026) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70111
Therkelsen, M. L. N., Hetland, L. E., Werge, M. P., Thing, M., Rashu, E. B., Nabilou, P., Kimer, N., Junker, A. E., Guiliani, A. M., Karsdal, M. A., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102251
Matsunaga, Y., Inoue, M.-K., Kanna, M., Asano, T., & Nakatsu, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177788
“In addition, the GLP-1 receptor agonist semaglutide has received FDA approval for ameliorating liver fibrosis [15].”
Zheng, H., & Han, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1942151
MASLD and MASH: Steatotic liver disease joins the deadly quartet
Xu, R., Abate, N., Stribling, R., & Su, R. (2026) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.93a.25117
“27 The phase 3 ESSENCE (Effect of Semaglutide in Subjects With Noncirrhotic Nonalcoholic Steato-hepatitis) trial 28 found that steatohepatitis resolved without worsening fi brosis in 62.9% of patients receiving semaglutide 2.4 mg once weekly, compared with 34.3% with placebo, with at least a…”
InfluentialRedefining Fatty Liver Disease: How Updated Nomenclature Reshapes Clinical Laboratory Diagnostics
Wei, R., Guan, Y., Zhai, M., & Zhao, X. (2026) · iLABMED · doi:10.1002/ila2.70070
“In contrast, the clinical efficacy of semaglutide, which targets upstream metabolic drivers such as obesity and IR, suggests that a broader diagnostic framework centered on metabolic dysregulation can support more effective therapeutic strategies [11].”
Stroes, A.-S. R., Kusters, D. M., Draijer, L. G., Bohte, A. E., Nederveen, A. J., de Groot, E., Benninga, M. A., Holleboom, A. G., Koot, B. G. P., & Hutten, B. A. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70148
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
“…( n = 534; mean age, 56.3 years), semaglutide 2.4 mg achieved resolution of metabolic dysfunction-associated steatohepatitis and improvement of liver fibrosis in 62.9% and 36.8% of patients with MASLD, respectively, with no efficacy difference across age groups in sub-group analyses [76].”
InfluentialFlavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies
Yan, S., Yang, H., Wang, Y., Zhu, L., Wang, B., Zhang, L., & Hao, Q. (2026) · Pharmaceuticals · doi:10.3390/ph19091393 · Cited by 1
“Early-phase studies should integrate population pharmacokinetics with exposure–response modeling, whereas later trials should use endpoint timing aligned with contemporary standards and include longer safety follow-up for products intended for chronic use [19,20].”
Molecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles
Chen, Q., Shevchenko, T., Zhan, D., Ma, N., Lefere, S., Boeckmans, J., Kock, J. D., Goethem, F. V., He, Y., Vanhaecke, T., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.025
Emerging Topics In Obesity Treatment in the Setting of Organ Transplantation
Maahs, E. D., Zimmerman, Z., Khungar, V., & Banini, B. A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00749-w
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
Leanza, G., Viola, V., Bemporad, J., & Napoli, N. (2026) · il Diabete · doi:10.30682/ildia2602f
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Zhang, K., Chen, Y., Ran, L., Tong, W., Dai, L., Yang, Z., Chen, Q., Zheng, J., & Hu, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1857676
“…clinical evidence indicates that, despite achieving fibrosis improvement in a proportion of patients compared with placebo (Harrison et al., 2024; Sanyal et al., 2025), these monotherapies demonstrate limited overall absolute benefit and considerable heterogeneity in treatment responses across…”
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
“…in promoting steatohepatitis resolution in a phase 2 trial [228], while the phase 3 ESSENCE trial confirmed that semaglutide 2.4 mg once weekly significantly increased both MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH compared with placebo [229].”
InfluentialKhanuja, P. K., Mohan, V., Martinez, A. P., Nellutla, M., Alamgir, M., Anjum, A., Ahmad, F. A. J., Oguntona, T. S., Saari, H. A. M. A., Suresh, D., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1860047
“In 2025, semaglutide, a GLP-1 agonist, received an indication for adults with MASH and moderate-to-advanced fibrosis for use in conjunction with diet and exercise, based on interim histologic results from the ESSENCE program (55, 56).”
MASLD: cuando el hígado deja de ser el único protagonista
Restrepo, J. C. (2026) · Hepatología · doi:10.59093/27112330.176
Liu, H., Zhang, M., & Tacke, F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s543657
Cai, L.-Y., Guan, Y., Hu, J., Sun, C.-Y., Ding, C., Zhang, X., Zeng, X., & Xie, W. (2026) · Liver International · doi:10.1111/liv.70846
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Kongala, B. P., Duty, K., & Ammar, H. (2026) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1650
Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations
Pathan, F. K., & Williams, K. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.05
Lee, S., Song, Y., Kim, S., Leprat, Q., Choi, I., Kim, J.-H., Lee, Y.-J., & Seo, H. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158772
Alam, A., Mahajan, K., Dutta, D., & Kamrul-Hasan, A. B. M. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103673
Mattina, A., Tarantino, I., & Pinzani, M. (2026) · Gut · doi:10.1136/gutjnl-2026-340432
Sebastiani, G., Lee, T.-H. “., Cordie, A., Cinque, F., Lake, J. E., Lazarus, J. V., Rockstroh, J. K., & Guaraldi, G. (2026) · The Lancet HIV · doi:10.1016/s2352-3018(26)00172-4
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Passos, P. R. C., Filho, V. O. C., Moraes, B. D. F., Silveira, I. B., SÜFFERT, L. C., & Cançado, G. G. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.030
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.